{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-26-001016","form_type":"8-K","ticker":"TGNT","cik":"0000846377","company_name":"Totaligent, Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.816169+00:00","generated_at":"2026-05-16T00:34:49.843305+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Totaligent signs binding LOI for JV with GloMed and call option to acquire GloMed for $3M cash + 15% equity","bullets":["GloMed has ~$10M annual revenue and ~$1M free cash flow; distributes biologics/devices in APAC via 20+ KOLs.","JV will combine Aetherium Medical platform with GloMed's infrastructure; no upfront cash; incremental revenue shared.","Call option to buy 100% of GloMed within 1 year for $3M cash plus 15% of Totaligent's fully diluted common stock.","Target JV closing March 22, 2026; subject to due diligence, definitive agreements, and PCAOB audit for option exercise.","Exclusivity through April 22, 2026; board seats: DeFeudis, Heath, Klarich; Totaligent appoints 3 seats for strategic control."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-001016","json":"https://secwatch.observer/filing/0001477932-26-001016.json","markdown":"https://secwatch.observer/filing/0001477932-26-001016.md","text":"https://secwatch.observer/filing/0001477932-26-001016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/846377/000147793226001016/0001477932-26-001016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/846377/000147793226001016/totaligent_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:34:49.843305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d73e1142c5246eff64184ef64124b60090a05ff","claim":"Totaligent, Inc. entered into Binding Letter of Intent with GloMed Solutions Limited Liability Company (effective 2026-02-22).","evidence_excerpt":"On February 22, 2026, Totaligent, Inc. (the “Company”) entered into a Binding Letter of Intent (the “LOI”) with GloMed Solutions Limited Liability Company (“GloMed”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/846377/000147793226001016/0001477932-26-001016-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"GloMed Solutions Limited Liability Company"},{"label":"Effective","value":"2026-02-22"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}